Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

AbbVie gets rights to Lupin's MALT1 program

Paul Bonanos
December 25, 2018 12:41 AM UTC

Lupin Ltd. (NSE:LUPIN; BSE:500257) granted AbbVie Inc. (NYSE:ABBV) exclusive, worldwide rights to a portfolio of mucosa-associated lymphoid tissue lymphoma translocation gene 1 (MALT1) inhibitors, which the U.S. pharma intends to develop for hematological cancers.

AbbVie will pay Lupin $30 million up front. The Indian company is eligible for $947 million in milestones, plus double-digit royalties, and will retain the program’s commercial rights in India...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Abbvie Inc.

Lupin Ltd.